AU Patent

AU2022312702A1 — Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Assigned to Novo Nordisk AS · Expires 2024-01-18 · 2y expired

What this patent protects

The invention relates to a tablet comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation such a tablet, and its use in medicine.

USPTO Abstract

The invention relates to a tablet comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation such a tablet, and its use in medicine.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022312702A1
Jurisdiction
AU
Classification
—
Expires
2024-01-18
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.